Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic

Oncology Times - OncTimes Talk

An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types.
At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice President and Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, reported early data from the PETRA study looking at the selective PARP 1 inhibitor saruparib under investigation as a potentially safer, yet more effective, alternative to the non-selective PARP 1/PARP 2 inhibitors currently licensed for prostate, ovarian, breast, and other cancers.
After announcing the new research findings at a clinical session at AACR, he met up with Oncology Times reporter Peter Goodwin to discuss the new data and their clinical potential.